ASX Penny Stocks To Watch In September 2026

The Australian stock market is poised for a positive start today, with the ASX expected to open higher following a rebound on Wall Street. Amidst this backdrop of fluctuating indices and evolving economic trends, investors are increasingly looking at opportunities in less conventional areas. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present valuable opportunities when they possess strong financial foundations and potential for growth.

Let's dive into some prime choices out of the screener.

Bravura Solutions (ASX:BVS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Bravura Solutions Limited offers software solutions for the wealth management and transfer agency sectors across Australia, the United Kingdom, New Zealand, and internationally, with a market capitalization of A$1.38 billion.

Operations: The company's revenue is primarily derived from two regions, with A$79.79 million generated in the Asia-Pacific (Apac) region and A$203.85 million from Europe, the Middle East, and Africa (Emea).

Market Cap: A$1.38B

Bravura Solutions demonstrates both strengths and challenges as a penny stock. The company reported significant revenue growth, with sales reaching A$282.55 million for the fiscal year ending June 2026, up from A$256.75 million the previous year. Net income also increased to A$110.92 million from A$74.23 million, showcasing improved profitability with a net profit margin of 39%. Despite these gains, earnings are forecasted to decline by an average of 8.1% annually over the next three years, and the management team lacks extensive tenure experience. Recent strategic moves include a share buyback program and entering into a new debt facility agreement with HSBC for up to A$100 million in funding.

• Jump into the full analysis health report here for a deeper understanding of Bravura Solutions.
• Assess Bravura Solutions' future earnings estimates with our detailed growth reports.

K&S (ASX:KSC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: K&S Corporation Limited offers transport and logistics solutions across Australia and New Zealand, with a market cap of A$425.60 million.

Operations: The company generates revenue through its key segments, which include Fuel (A$203.28 million), Australian Transport (A$496.64 million), and New Zealand Transport (A$79.01 million).

Market Cap: A$425.6M

K&S Corporation Limited faces both opportunities and challenges as a penny stock. The company's revenue for the fiscal year ended June 2026 was A$738.61 million, slightly down from A$756.86 million the previous year, with net income decreasing to A$22.78 million from A$29.2 million. While K&S maintains high-quality earnings and its interest payments are well covered by EBIT, its return on equity remains low at 6%. The dividend yield of 4.18% is not fully supported by free cash flow, and recent announcements include a reduced dividend of A$0.06 per share for the six months ended June 2026.

• Get an in-depth perspective on K&S' performance by reading our balance sheet health report here.
• Learn about K&S' historical performance here.

Mesoblast (ASX:MSB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products in Australia and has a market cap of A$3.08 billion.

Operations: The company generates revenue of $120.25 million from the development and commercialization of its allogeneic cellular medicines platform.

Market Cap: A$3.08B

Mesoblast Limited, while not yet profitable, has shown significant revenue growth with US$120.25 million reported for the fiscal year ending June 2026, up from US$17.2 million the previous year. The company is advancing its regenerative medicine products, notably rexlemestrocel-L for chronic low back pain, which could tap into a potential market exceeding US$10 billion annually in the U.S. alone with minimal market penetration. Despite a net loss of US$57.5 million, Mesoblast's strategic focus on innovative therapies and strong intellectual property portfolio positions it well within the competitive biotech sector as it progresses through pivotal clinical trials and regulatory pathways.

• Click here and access our complete financial health analysis report to understand the dynamics of Mesoblast.
• Gain insights into Mesoblast's outlook and expected performance with our report on the company's earnings estimates.

Turning Ideas Into Actions

• Embark on your investment journey to our 392 ASX Penny Stocks selection here.
• Seeking Other Investments? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com